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Title:  What can the treatment of Parkinson's disease learn from dementia care; applying a bio-1 
psycho-social approach to Parkinson's disease. 2 
Background. Within contemporary medical practice Parkinson’s Disease (PD) is treated using a 3 
biomedical, neurological approach, which although bringing numerous benefits can struggle to 4 
engage with how people with PD experience the disease.  A bio-psycho-social approach has not yet 5 
been established in PD, however bio-psycho-social approaches adopted within dementia care 6 
practice could bring significant benefit to PD care.  7 
Methods.  This paper summarises existing bio-psycho-social models of dementia care, and explores 8 
how these models could also usefully be applied to care for PD.  Specifically, this paper adapts the 9 
bio-psycho-social model for dementia developed by Spector and Orrell (2010), to suggest a bio-10 
psycho-social model which could be used to inform routine care in PD. 11 
Results. Drawing on the biopsychosocial model of Dementia put forward by Spector & Orrell (2010), 12 
this paper explores the application of a bio-psycho-social model of PD.  This model conceptualises 13 
PD as a trajectory, in which several inter-related fixed and tractable factors influence both PD’s 14 
symptomology and the various biological and psychosocial challenges individuals will face as their 15 
disease progresses.  Using an individual case study, this paper then illustrates how such a model can 16 
assist clinicians in identifying suitable interventions for people living with PD. 17 
Conclusion.  This model concludes by discussing how a bio-psycho-social model could be used as a 18 
tool in PD’s routine care.  The model also encourages the development of a theoretical and practical 19 
framework for the future development of the role of the PD specialist nurse within routine practice. 20 
Implications for practice.  A biopsychosocial approach to Parkinson’s Disease provides an 21 
opportunity to move towards a holistic model of care practice which addresses a wider range of 22 
factors affecting people living with PD.  The paper puts forward a framework through which PD care 23 
practice can move towards a biopsychosocial perspective.  PD specialist nurses are particularly well 24 
placed to adopt such a model within routine clinical practice, and should therefore be encouraged 25 
within PD services. 26 
27 
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Summary Statement of implications for practice 31 
What does this research add to existing knowledge in Gerontology? 32 
 This research shows how theoretical perspectives developed within dementia care research 33 
can usefully be applied to the care of people with Parkinson’s Disease. 34 
 This research puts forward a bio-psycho-social approach to care for people living with 35 
Parkinson’s Disease.  36 
 37 
What are the implications of this new knowledge for nursing care with older people? 38 
 A biopsychosocial model of PD provides practitioners with a tool through which they can 39 
better identify and address the problems people living with PD routinely face. 40 
 Parkinson’s Disease nurse specialists are well placed to deliver such a model, but require 41 
support to do so. 42 
 43 
How could the findings be used to influence policy or practice or research or education? 44 
 This model encourages research to recognise all aspects that PD has on the lives of people 45 
living with PD, and encourages a research agenda which addresses their concerns. 46 
 A biopsychosocial model of PD can support the design and development of holistic PD care 47 
services. 48 
49 
 
 
Introduction 50 
Parkinson’s Disease (hereafter PD) is a progressive neurological disorder, of unknown aetiology, 51 
which currently affects 10 million people worldwide (Parkinson’s Disease Foundation 2013; 52 
Pringsheim et al 2014).  While a neurological and pharmacological approach to PD therapy 53 
concerned with motor symptomology can alleviate many of PD’s symptoms, this treatment model 54 
also encourages an under-recognition and under-treatment of many of PDs most distressing 55 
experiences, leading to gaps between clinical priorities and patient need (Gibson 2016).  This paper 56 
argues that the bio-psycho-social approaches developed within dementia care research can 57 
contribute much to PD’s routine care [Downs et al 2008; Spector & Orrell 2010).  By adapting models 58 
of care used in dementia to PD, PD’s routine care can better recognise the full range of patient’s 59 
experiences as well as those prioritised within neurological approaches to PD therapy (Playfer 2007).  60 
After examining the medical models of PD and dementia and its critiques, this paper draws on a case 61 
study to explore how a bio-psycho-social model can be applied to PD, and the implications such an 62 
approach may have for PD’s routine care. 63 
Explanatory models; PD and Dementia 64 
The Psychiatrist and Anthropologist Arthur Kleinman’s concept of explanatory models provides a 65 
means to conceptualise how illnesses are differentially defined, perceived and treated by 66 
practitioners, patients and society at large (Kleinman 1988).  Although the predominant explanatory 67 
model for an illness offers a shared perspective through which an illness may be understood, how 68 
these models are interpreted differs significantly between clinicians and patients. Such differences 69 
lead to significant gaps between what clinicians identify as their priorities and patients own 70 
experiences (Downs et al 2006).  Appreciating these differing explanatory models therefore provides 71 
clinicians with a means of better understanding their patient’s experiences and how they may differ 72 
from their own perspectives.  In doing so, Kleinman’s original concept can assist clinicians in better 73 
identifying and addressing patient need. 74 
 
 
Based in neurology, the most commonplace explanatory model for PD within medicine 75 
conceptualises the disease as the breakdown of striatal dopamine, manifested through the 76 
progressive development of motor symptomology and treated through dopaminergic and related 77 
therapies (Playfer 2007).  This mono-disciplinary model has been criticized for under-recognising and 78 
under-treating much of PD’s symptomology (Van Der Marck et al 2009; Gibson 2016). Greater 79 
attention is now being paid to PD’s non-motor symptomology within routine care, inclusive of 80 
symptoms such as dementia (Aarsland et al 2005), mood disorders (Leentjens 2004), hallucinations 81 
(Gibson et al 2013), impulse control disorders (Wu et al 2009), or the side effects of dopaminergic 82 
therapies (Matson 2002).  Questions have also been raised regarding the relative impacts of PD’s 83 
symptoms on quality of life, with research showing that PD patient’s complaints diverge significantly 84 
when compared to those symptoms prioritised in PD’s routine therapy (Tickle-Degnen & Doyle Lyons 85 
2004).  For example, while patients highlight mental, functional and psychosocial impairments as 86 
their biggest problems, clinicians routinely judge motor symptoms which respond to anti-Parkinson’s 87 
drugs as most distressing (Abudi et al 1997, Rahman et al 2008, Politis et al 2010). Although useful 88 
for identifying and addressing disease pathology, PD’s conceptualisation within medicine therefore 89 
differs greatly when compared to patient’s judgements about PD, leading to significant differences 90 
between clinical priorities and patients lived experiences. 91 
Rahman et al argue for a paradigm shift in PD therapy, comprising a move away from a singular 92 
focus on motor symptoms towards a multi-disciplinary, holistic approach which better reflects the 93 
complexity of the problems arising in PD (Rahman et al 2008).  However, despite such an approach 94 
being previously recommended within national and international guidance regarding PD’s routine 95 
treatment (Parkinson’s UK 2015; Hellqvist & Bertero 2015), such a multi-disciplinary focus has not 96 
yet become the norm (Politis et al 2010; Parkinson’s UK 2015). This suggests that a shift to more 97 
holistic and multidisciplinary models of care has not yet taken place. 98 
The explanatory model for Dementia provides useful insights in relation regarding how such a 99 
paradigm shift in PD towards multidisciplinary treatment and holistic care can be encouraged.  100 
 
 
Historically the lay model for dementia was ‘senility’, in which memory losses were viewed as a 101 
natural and expected part of older age (Downs et al 2006).  Only relatively recently has a 102 
neuropsychiatric model of dementia been developed, based on advances in neuroscience and 103 
medical imaging which have led to some of the specific disease pathologies leading to dementia 104 
being identified (Fox 1989; Downs et al 2006).  The growth of this neuropsychiatric model, alongside 105 
political concerns about demographic ageing has contributed to the recent dramatic growth in 106 
scientific and political concern being paid to dementia, demonstrated in the last decade by 107 
increasing international calls for research, such as the UK Prime Minister’s challenge for dementia, 108 
and the French National Alzheimer Plan.   109 
The neuropsychiatric model of PD has also been robustly criticised. First, it has not yet led to 110 
effective therapies. The few dementia drug treatments currently available only have limited or 111 
modest efficacies, numerous dementia trials have failed, while what few non-drug treatments are 112 
available have either limited evidence for their efficacy or are only rarely offered by services, despite 113 
evidence for their effectiveness (Dickinson et al 2016). Examples of such non-drug therapies include 114 
Cognitive Stimulation Therapy (Spector & Orrell 2006; World Alzheimer Report 2011).  The 115 
neuropsychiatric model of dementia has also been criticised for holding ‘an accompanying tendency 116 
to attribute the experience of persons with dementia exclusively to a disease process’, thereby 117 
ignoring its psychological or social experience [Cotrell & Schultz 1993 pp. 205].  Each of these issues 118 
can contribute to poor care practices, leading to calls for more holistic approaches to Dementia Care 119 
such as the UK Government’s Living Well with Dementia strategy or UK Alzheimer’s Society 120 
‘Dementia Friends’ initiative (Mitchell et al 2016). 121 
The paucity of effective clinical treatments for dementia has arguably given space for alternative 122 
explanatory models for dementia to develop.  Of greatest significance is the social model of 123 
dementia.  Exemplars of the social model include Sabat’s concern over the self in dementia (Sabat & 124 
Harre 1994) and Kitwood’s (1997) seminal work on personhood in dementia. Key to the social model 125 
of dementia is the postulation that dementia is experienced through the ‘interplay of neurological 126 
 
 
impairment, physical health, sensory acuity, personality, biography and experience, relationships 127 
and social resources’ (Kitwood 1997). The various problems associated with dementia, such as 128 
memory loss, confusion, agitation or wandering are not simply the result of cognitive breakdown. 129 
They are also reflections of a person’s shifting ability to make sense of the world.  Not just biological 130 
change, it is what Kitwood (1997) famously termed ‘malignant social psychology’ which ‘deprives a 131 
neurologically impaired individual of their ‘personhood’, or their socially determined right to exist in 132 
the world as individuals’ that leads to many of the problems experienced in dementia.  To 133 
successfully care for those with dementia, dementia care practitioners must therefore show a 134 
heightened sensitivity to the place people with dementia occupy in their individual social worlds.  135 
This model has also been critiqued, with subsequent developments moving towards a ‘rights’ based 136 
approach to dementia, which calls for people with dementia to be accorded full rights as citizens, 137 
fully able to participate in life (Bartlett & O’Connor 2010; World Health Organisation 2015).   138 
Dementia; a biopsychosocial model 139 
FIG 1 HERE 140 
Expanding on the social model, recent work in dementia care research argues for a biopsychosocial 141 
approach to dementia (Spector & Orrell 2010, Sabat 2008). This approach argues for a synthesis 142 
between medical and social models of illness, and integrates the biological changes and physical, 143 
mental and emotional states occurring in dementia with the psychosocial impacts resulting from an 144 
individual’s changing social environment. Spector and Orrell (2010) integrate the various 145 
biopsychosocial approaches in dementia into a single model (fig 1), which they suggest can be used 146 
as a tool for understanding individual cases. This model encourages that dementia is recognised as 147 
‘something which is malleable and where change, adaptation and improvement is possible’ [Downs 148 
et al 2008 p959).  In doing so, this model moves beyond the separation of the biological and the 149 
 
 
social to instead identify the inter-relationships occurring between the two, allowing dementia 150 
interventions to be tailored according to individual need.  151 
This model highlights the various biological and psychosocial challenges people face as they move 152 
through their illness; from initial symptoms and diagnosis, through disease progression, to end of life 153 
care and death.  The model includes fixed factors such as age, historic physical health, education 154 
level or previous life experiences, and tractable factors which are amenable to interventions, such as 155 
mood, current physical health or the actions and reactions of people within an individual’s social 156 
circle. Finally, the model also recognises how ‘excess’ disability in dementia results from social 157 
practices including medical and social care.  By understanding the interplay between biological and 158 
psychosocial factors which may influence a person’s physical and emotional states, and how these 159 
change as individuals move through the illness, this model can be used to inform best practice in 160 
dementia therapy and care. 161 
 162 
A bio-psycho-social model of PD 163 
FIG 2 HERE 164 
Drawing upon Spector & Orrell (2010) alongside qualitative data from a study of men’s experiences 165 
of living with PD (Gibson & Kierans 2016; Gibson 2016), this paper puts forward a bio-psycho-social 166 
model for PD (fig 2). The qualitative study examined 15 men’s accounts of living with PD, the 167 
biological and psycho-social factors influencing their experience of PD, and their response to PD as it 168 
progressed.  Findings from this study are reported elsewhere (Gibson & Kierans 2016; Gibson 2016).  169 
Although experiences varied across individuals, several commonalities emerged which contributed 170 
to the development of this model. An initial onset of symptoms eventually led to patients seeking a 171 
diagnosis, when many men found their most taken for granted assumptions about life changing.  172 
With time, most could find ways to integrate the physical, psychological and social changes PD 173 
 
 
brought into their lives, drawing on a range of fixed and tractable biological and social factors (listed 174 
in fig 2) when doing so.  175 
After undergoing a period of disruption and adaptation early in their illness, most men adopted a 176 
circular and iterative approach to coping with PD.  As their PD progressed, most men found that 177 
their coping strategies began to fail; for example, they could no longer manage long loved hobbies, 178 
while even everyday occupations eventually became too difficult for many to accomplish. But people 179 
found new ways to cope with these problems. Many involved medicine, for example increasing 180 
medication dosages or adding further medications to their regimes to address specific problems. 181 
Others were in men’s individual social lives and included adapting how they completed their 182 
everyday activities, or changing how they interacted with other people (for example taking up less 183 
strenuous hobbies or pastimes). These issues each had consequences for men’s everyday lives. By 184 
finding new ways to adapt to their illness and the problems it caused, several men could successfully 185 
cope with their PD.  Importantly though, men continually had to adapt their responses to PD’s 186 
worsening symptoms. This process of decline and adaptation could take place well into disability, 187 
however as PD worsened accomplishing these adaptations became more difficult, leaving people 188 
potentially vulnerable to both lower quality of life, declining mood and an exacerbation of their PD 189 
symptoms if they could no longer adapt to their PD. 190 
At its core, adopting such a model in PD care encourages clinicians to consider PD’s effects on the 191 
totality of those with PD’s lives, and to identify interventions with can help people cope with all the 192 
problems they will face.  By acknowledging this circular experience medical and psycho-social 193 
interventions can be designed which are appropriate to people’s individual illness stage and to their 194 
changing needs.  At the biological or clinical level, such interventions include increasing PD 195 
medications or introducing new drug therapies. Interventions at a psychological or psychosocial level 196 
may be tailored to help people to cope with the onset of symptoms, to retain everyday occupations, 197 
or come to terms with their progressive losses in abilities as their PD worsens.  In addition, the 198 
 
 
consequences of current interventions, such as the side effects resulting from increasing medication 199 
loads can more easily be identified and managed.  To explore the utility of adopting a bio-psycho-200 
social approach in PD this paper now turns its attention to ‘Tony’, a man in middle age living with 201 
moderate PD. 202 
Applying a bio-psycho-social approach to PD; the case of ‘Tony’ 203 
Tony (a pseudonym) was a 62-year-old man with moderate PD, who took part in the qualitative 204 
research described above. At the time of interview, Tony had been living with PD for 12 years.  Tony 205 
also had a history of depression, which forced him to take early retirement.  Tony took several PD 206 
drugs but noticed that they were becoming less effective, meaning his dosages had to be increased 207 
more and more frequently.  Tony was also experiencing motor side effects, including ‘off periods’, 208 
where his symptoms suddenly deteriorated at the end of a medication dose, and peak dose 209 
dyskinesia’s or the involuntary movements associated with dopaminergic therapies (Matson 2002). 210 
Consequently, Tony struggled more and more with his various daily activities; he didn’t know how 211 
much longer he would be able to drive, sail his fishing boat or walk his dogs on the beach near his 212 
home.  Living in a rural and isolated area, Tony also struggled to drive to his local village to do his 213 
shopping, to see his GP, or get to the local PD clinic, 40 miles away. Tony was satisfied with his care 214 
team, but struggled to contact his local PD specialist nurse for advice or support when he needed it. 215 
Of greatest significance, the increases to his medication dosage, alongside more frequent side 216 
effects meant Tony worried about how fast his condition was worsening, what would happen in the 217 
future and how much time he had left before his PD got ‘bad bad’ (Gibson 2016).  Also, given his 218 
history of depression, Tony particularly feared that his worsening PD could cause another bout of 219 
depression, leading him to consider suicide rather than live with both the severe disability and 220 
severe depression he feared his PD would bring. 221 
 
 
Applying a bio-psycho-social model to Tony’s care raises several implications for his PD care.  For 222 
Tony, it was both declining activities of daily living and increases in medication side effects that 223 
posed a threat to his quality of life.  Identifying what these impacts may be, and whether therapies 224 
could assist Tony’s continued social participation should therefore be investigated.  Tony had also 225 
become very aware of the changes in bodily functioning caused by medications, planning his days 226 
around the times when his medications were functioning well.  In addition to their beneficial effects, 227 
Tony also had to manage a whole range of side effects.  Dyskinesia and ‘off’ periods were both side 228 
effects of PD’s therapy which Tony had to deal with on a daily basis.  Tony had developed extensive 229 
knowledge of his medications and their effects over time, using this knowledge to understand and 230 
manage his illness. While bringing benefits new medications were also interpreted as a deterioration 231 
in his condition, leading Tony to worry about how much worse his condition might get.  Decisions 232 
about medications should therefore be made in collaboration with the patient, paying attention not 233 
only to motor function, but also to how tolerable side effects may be.  Furthermore, clinicians should 234 
investigate how medication usage is understood by patients, and how medication management 235 
influences this experience.  In this respect, the biopsychosocial model shows up the need to take 236 
greater account of the ‘real world’ consequences of both PD’s symptoms and PD therapy, and the 237 
need to involve patients in making informed decisions about their treatments. 238 
Going beyond the pharmacological management of PD, a biopsychosocial model also gives 239 
important insights into the inter-relatedness of PD symptoms, PD care and wider health and quality 240 
of life.  PD should therefore not be treated in isolation, but should be understood within the context 241 
of a patient’s wider health. Tony gave clear indications of his priorities for treatment.  Given Tony 242 
linked his depression and PD motor symptoms, importance should be paid to helping Tony manage 243 
his depression within the context of his PD.  In addition, helping Tony manage and come to terms 244 
with his body’s physical decline and the commensurate loss of hobbies, pastimes and other activities 245 
 
 
linked to a sense of self should also be priorities for his care.  Such forms of support should reflect a 246 
concern for PD’s effects within the context of Tony’s life and lived experience. 247 
In the case of Tony, pharmacological therapies can be complemented by psycho-social interventions 248 
such as physiotherapy, psychotherapy or occupational therapy, each at appropriate stages of his 249 
illness.  Psychotherapy can help manage expectations over bodily decline as well as mood disorders 250 
associated with PD (Brown et al 2011). In conjunction with medications physiotherapy can assist 251 
with supporting physical movement (Tomlinson et al 2013). Occupational therapy services are well 252 
placed to assist with occupations; either through using assistive technologies, aids and adaptations, 253 
or simply in supporting people with PD to carry out daily tasks (Dixon et al 2007; Foster et al 2014). 254 
More widely, a bio-psycho-social model helps to identify periods during an individual’s illness where 255 
assistance may be more necessary.  Within men’s accounts of living with PD, three points of 256 
disjuncture become prominent, in which careful attention to patient experience is required. First 257 
during and in the initial period of diagnosis, as people first experience a deterioration in function 258 
after commencement of treatment (the end of what Solimeo 2008 calls the medication honeymoon) 259 
and when medications begin to lose their overall effect, or when side effects start to become 260 
intolerable.  By paying attention to the totality of a person’s experience, such a model can assist 261 
clinicians in providing both more holistic forms of care, and more personalised therapies better 262 
suited to address individual patients’ needs. 263 
Conclusion 264 
A bio-psycho-social approach provides a means through which we can gain greater insights into PD’s 265 
experience, which better reflect patient’s needs.  This model does however have several limitations.  266 
The empirical work used in the application of this model to PD is limited to a qualitative study of 15 267 
men’s experiences of PD.  This small and unrepresentative sample therefore limits its 268 
generalizability. Further refinement which demonstrates the model’s relevance among different 269 
 
 
patient groups, for example with women with PD or people of differing ages is also necessary.  The 270 
applicability of bio-psycho-social approaches drawn from dementia care to PD can also be 271 
questioned.  Despite a significant degree of overlap in symptoms and age profiles PD and dementia 272 
are separate illnesses with their own aetiologies, symptomologies, effects and courses.  While the 273 
structure of the model bears similarities, the actual processes or activities which drive PD’s 274 
experiences will be different, as will be the solutions. There is also significant overlap between the 275 
factors identified in this model, with physical activities such as dance crossing over multiple fixed 276 
and tractable factors (Spector & Orrell 2010; McGill et al 2014). Although emerging from empirical 277 
research, this model has also not been tested empirically, so the factors which may contribute to 278 
wellbeing in PD may well be distinct compared to those listed in this model. Future research applying 279 
the model to nursing practice will help identify how such a model could best be implemented within 280 
routine care, alongside which factors are most relevant, and which may be most amenable to 281 
change. 282 
Despite these limitations, the bio-psycho-social model of PD detailed above is one avenue through 283 
which Rahman et al’s (2008) paradigm shift towards holistic PD care can be accomplished.  It is 284 
important to note that this model does not seek to replace a biological and neurological model of 285 
PD; such a model remains the best structure through which future therapies for PD will be achieved.  286 
However, the strength of adopting a bio-psycho-social approach to PD is that it encourages a greater 287 
appreciation of the psychological and social factors associated with the disease, which continue to 288 
be under-recognised within its care (McGill et al 2014).  As multi-disciplinary treatment of PD has 289 
grown, the model contributes to debate about how far PD care addresses the lived experiences of its 290 
patients, while providing a practical guide through which clinicians can consider PD’s wider 291 
symptoms.  For example, the model can identify common points of difficulty or mechanisms of 292 
change, identify common psychosocial approaches, or reduce excess disability for people with PD.  293 
 
 
Parkinson’s Disease Specialist Nurses are particularly well placed to engage with this model given 294 
their role in providing individualised psychological and social support (Hellqvist & Bertero 2015; 295 
Pedersen et al 2017). The role of Parkinson Disease specialist nurses includes co-ordinating the 296 
range of services used in routine PD care, assisting in the delivery of and adherence to drug 297 
treatments, and providing a central point of information and emotional support to people with PD 298 
(Bhidayasiri et al 2016, Theed et al 2016).  However, research suggests that excessive workloads and 299 
wider resource demands may threaten PD nurse specialist’s ability to perform this role (Reynolds et 300 
al 2000; Hellqvist & Bertero 2015).  The continued expansion of PD nurse specialists should therefore 301 
be encouraged, but with sufficient allocation of resources to ensure that their roles can be delivered 302 
effectively. The model described also contributes to the development of a theoretical and practical 303 
framework for the PD nurse specialist role. This model can also influence PD care pathways by 304 
providing a structure for when and how interventions should be offered.  In relation to their 305 
biopsychosocial model of dementia, Spector and Orrell (2010 pp964) conclude by stating that their 306 
model ‘helps to work against (the assumption that the actions of a person are solely attributed to 307 
the illness) by taking a more individual and biopsychosocial perspective.  In the context of PD, this 308 
model hopes to do the same. 309 
Implications for Practice 310 
 A biopsychosocial model of PD promotes a wider recognition of the environmental and 311 
social factors which affect people living with PD, and suggests ways in which health service 312 
interventions can be delivered. 313 
 The above model illustrates how a person’s needs may change as they move through the PD 314 
journey, and the dimensions in which they may need assistance and support. 315 
 Parkinson’s disease nurse specialists are well placed to deliver a biopsychosocial model of PD 316 
care, but need greater support in order to fulfil this role. 317 
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